Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

andidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unrespectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development.

OncoGenex' Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial initiation and completion dates, patient enrollment targets, proposed amendments to our ongoing clinical trial design and the timing and possibility for approval by the FDA thereof, the timing and costs of our product development activities and the potential benefits of our product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk of delays in our expected clinical trials and the uncertainties regarding patient enrollment rates, the risk that the FDA does not approve our proposed amendment to the Saturn trial design in a timely fashion or at all, the risk that our product candidates do not obtain the requisite regulatory approvals to commercialize, the risk that new developments in the rapidly evolving prostate cancer therapy landscape require additional changes in our clinical trial design or lim
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... On Tuesday, July 1, 2014, ... the 116 th Judicial District Court in ... RegenLab USA, LLC ("Defendant") for Tortious ... through false and misleading actions, fraud, fraud-in-the-inducement, business ... through libel, disparagement, defamation, misrepresentation, and violating the ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
(Date:7/23/2014)...  Mezzion Pharma Co. Ltd., announced that it has ... udenafil to treat adolescents who have undergone the Fontan ... program will follow protocols developed by a subcommittee made ... a multi-center clinical research network funded by the National ... Institutes of Health (NIH). The studies, ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2
... (Nasdaq: BMRN ) today hosted a Research ... team and industry experts provided an update on BioMarin,s ... pipeline. "We believe 2011 has been a ... and early stage clinical development programs," said Jean-Jacques Bienaime, ...
... Modern Materials Division of Heraeus Kulzer, LLC, the ... The division has been the leader in the U.S. dental ... Modern Materials was founded in 1946 in St. Louis, ... chemist, was "Mr. Inside" while Mr. Piper, the consummate salesman, ...
Cached Medicine Technology:Highlights from BioMarin's Research & Development Day 2Highlights from BioMarin's Research & Development Day 3Highlights from BioMarin's Research & Development Day 4Highlights from BioMarin's Research & Development Day 5Highlights from BioMarin's Research & Development Day 6Heraeus' Modern Materials Division Celebrates 65th Anniversary 2Heraeus' Modern Materials Division Celebrates 65th Anniversary 3
(Date:7/23/2014)... Steven Reinberg HealthDay Reporter ... Many obese and overweight American children and teens look ... fine, U.S. health officials reported Wednesday. "Being overweight ... as high blood pressure, high cholesterol and diabetes," said ... U.S. Centers for Disease Control and Prevention,s National Center ...
(Date:7/23/2014)... The next episode of “Extreme Weight Loss” ... was physically fit through childhood and adolescence. After becoming ... heart-wrenching decision to give her son up for adoption. ... years, and she punished herself by overeating, gaining nearly ... non-competitive approach to weight loss transformations, “Extreme Weight Loss” ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... Painful or itchy skin lesions could be a warning ... have multiple lesions that are suspicious looking, and those ... for non-melanoma skin cancers," study author Dr. Gil Yosipovitch, ... said in a Temple University Health System news release. ... patients who were confirmed to have skin cancer lesions ...
(Date:7/23/2014)... supports a growing body of research suggesting a ... in treating postmenopausal breast cancer, with fewer detrimental ... standard anti-hormone therapies. The study will be published ... Reproductive Biology and Endocrinology . , Breast ... women in the United States. Approximately 70% of ...
Breaking Medicine News(10 mins):Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 2Health News:Many Obese U.S. Kids Think They're Thinner Than They Are 3Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... Amanda Gardner HealthDay Reporter , FRIDAY, Dec. 16 ... who receive targeted radiation to the breast after a lumpectomy ... only about a third of these women were considered "suitable" ... study published in the Dec. 16 online issue of the ...
... SAGE and the European Society of Cardiology (ESC) ... Journal: Acute Cardiovascular Care. The first issue will be ... represents over 70,000 cardiology professionals across Europe and the ... including publishing seven of the world,s leading cardiology journals. ...
... 17 (HealthDay News) -- The busy holiday season may disrupt ... it is especially important to remember to look after your ... people to consume sugary treats and drink alcoholic beverages more ... General Dentistry, said in an academy news release. "Additionally, ...
... Will a drug used to treat childhood acute lymphoblastic leukemia ... UB associate professor of pharmaceutical sciences, Javier G. ... research and clinical practice, has focused recent efforts on trying ... study in the Journal of Clinical Oncology looked for the ...
... Scientists may have a way to double the efficacy ... Sciences University scientists have devised a way to reduce lung ... caused by radiation therapy., "Radiation is a great therapy ... Dynan, biochemist and Associate Director of Research and Chief, Nanomedicine ...
... FRIDAY, Dec. 16 (HealthDay News) -- Chronic pain can ... the affected partner,s ability to cope with the pain, ... shown that validation of a spouse,s emotions (showing respect ... invalidation of emotions (showing hostility or no interest) increases ...
Cached Medicine News:Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 2Health News:Targeted Radiation for Breast Cancer May Be Overused: Study 3Health News:Sage and European Society of Cardiology extend publishing partnership 2Health News:Dentist Gives Advice to Keep Holiday Smiles Bright 2Health News:Childhood cancer drugs cure now, may cause problems later, UB research shows 2Health News:Scientists may be able to double efficacy of radiation therapy 2Health News:Spouse's Reaction May Affect Pain Management 2
Large image and wide-angle design....
Large-image field with titanium couplers for c-mount scopes. 30mm focal length....
High intensity lamp with built-in, switchable spare lamp. Low-noise fan with reduced air turbulence....
PDA application listing specific ICD-9 coding listed in new Medicare National Coverage Determinations....
Medicine Products: